AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
For hepatic failure, stem cell transplantation has been chosen as an alternative therapy, especially for mesenchymal stem cells (MSCs). The aim of this study was to investigate the effect of eugenol (EUG) on the in vivo antifibrotic activity of adipose tissue-derived MSCs (AT-MSCs) and the underlying mechanism. After characterization of MSCs, rats were divided into five groups, Group 1 (normal control), Group 2 (CCl4), Group 3 (CCl4 + AT-MSCs), Group 4 (CCl4 + EUG) and Group 5 (CCl4 + AT-MSCs + EUG). Biochemical and histopathological investigations were performed. Furthermore, expression of type 1 collagen, α-SMA, TGF-β1, Smad3 and P-Smad3 was estimated. Compared to the single treatment with AT-MSCs, the combination treatment of the fibrotic rats with AT-MSCs and EUG significantly improved the plasma fibrinogen concentration, IL-10 level and proliferating cell nuclear antigen expression, and also significantly decreased the serum levels of liver enzymes, IL-6, IL-1β, TNF-α, type III collagen, hyaluronic acid, hydroxyproline and the TGF-β growth factor. Furthermore, the combination treatment significantly decreased the hepatic expression of fibrotic markers genes (Type 1 collagen and α-SMA) and proteins (α-SMA, TGF-β1 and phospho-Smad3) more than the treatment with AT-MSCs alone. We demonstrated that the combination treatment with EUG and AT-MSCs strongly inhibited the advancement of CCl4-induced hepatic fibrosis, compared with AT-MSCs alone, through TGF-β/Smad pathway inhibition. This approach is completely novel, so more investigations are necessary to improve our perception of the underlying molecular mechanisms accountable for the effects of EUG on the antifibrotic potential of AT-MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nowadays, researchers have increasingly demonstrated that combining MSC-based therapies with drugs, such as simvastatin, eugenol, imatinib, Juzentaihoto, Ferulic acid, and fucoxanthin, can improve the intervention efficacy in animal models [377–382].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [377]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“If inappropriately handled, hepatic fibrosis may proceed to cirrhosis, resulting in patients requiring hepatic transplantation [11,12].”
BackgroundRemmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
Mesenchymal Stem Cells as Therapeutics
Parekkadan, B., & Milwid, J. M. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105309 · Cited by 759 · cited 1×
“MSCs also present many other features, like no adverse reactions related to MSCs transplant, and long-term storage without considerable loss of potency [4].”
BackgroundTGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 2×
“uring the past fe years, researchers have reported that S s counter and exert therapeutic benefits against hepatic fibrosis [18,19].”
BackgroundTerai, S., Ishikawa, T., Omori, K., Aoyama, K., Marumoto, Y., Urata, Y., Yokoyama, Y., Uchida, K., Yamasaki, T., Fujii, Y., et al. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0542 · Cited by 491
Cytokine interactions in mesenchymal stem cells from cord blood
LIU, C., & HWANG, S. (2005) · Cytokine · doi:10.1016/j.cyto.2005.11.003 · Cited by 211
Strategies for anti-fibrotic therapies
Rosenbloom, J., Mendoza, F. A., & Jimenez, S. A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.007 · Cited by 170
Lotfy, A., Salama, M., Zahran, F., Jones, E., Badawy, A., & Sobh, M. (2014) · International Journal of Stem Cells · doi:10.15283/ijsc.2014.7.2.135 · Cited by 159
Quantitative Evaluation of Liver Function with MRI Using Gd-EOB-DTPA
Ryeom, H. K., Kim, S., Kim, J.-Y., Kim, H.-J., Lee, J. M., Chang, Y., Kim, Y., & Kang, D.-S. (2004) · Korean Journal of Radiology · doi:10.3348/kjr.2004.5.4.231 · Cited by 146
Bone marrow‐derived mesenchymal stem cell attenuates skin fibrosis development in mice
Wu, Y., Huang, S., Jirigala, E., Ma, K., Yang, S., Sun, T.-Z., & Fu, X. (2013) · International Wound Journal · doi:10.1111/iwj.12034 · Cited by 134
Fathy, M., Fawzy, M. A., Hintzsche, H., Nikaido, T., Dandekar, T., & Othman, E. M. (2019) · Molecules · doi:10.3390/molecules24213979 · Cited by 99 · cited 2×
“It as reported that E exerted various phar acological activities [20], and sho ed a hepatoprotective effect by improving the hepatic antioxidant capacity and declining the inflammation via the downregulation of the iNOS pathway [14].”
BackgroundSelf-citationIn Vivo Tracking and Comparison of the Therapeutic Effects of MSCs and HSCs for Liver Injury
Li, Q., Zhou, X., Shi, Y., Li, J., Zheng, L., Cui, L., Zhang, J., Wang, L., Han, Z., Han, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062363 · Cited by 90 · cited 1×
“They are immunomodulatory, can directly differentiate to new hepatocytes, have antifibrotic properties, can promote tissue repair and also inhibit hepatic stellate cells activation [5].”
BackgroundCharacterization of Amniotic Stem Cells
Koike, C., Zhou, K., Takeda, Y., Fathy, M., Okabe, M., Yoshida, T., Nakamura, Y., Kato, Y., & Nikaido, T. (2014) · Cellular Reprogramming · doi:10.1089/cell.2013.0090 · Cited by 78
Self-citationNitric oxide augments mesenchymal stem cell ability to repair liver fibrosis
Ali, G., Mohsin, S., Khan, M., Nasir, G. A., Shams, S., Khan, S. N., & Riazuddin, S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-75 · Cited by 70
Fathy, M., Khalifa, E. M. M. A., & Fawzy, M. A. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.11.031 · Cited by 66 · cited 4×
“) injected daily at a dose 10 mg/kg [14].”
BackgroundInfluentialSelf-citationKim, G., Eom, Y. W., Baik, S. K., Shin, Y., Lim, Y. L., Kim, M. Y., Kwon, S. O., & Chang, S. J. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.10.1405 · Cited by 54 · cited 2×
“uring the past fe years, researchers have reported that S s counter and exert therapeutic benefits against hepatic fibrosis [18,19].”
BackgroundJang, Y. O., Cho, M.-Y., Yun, C.-O., Baik, S. K., Park, K.-S., Cha, S.-K., Chang, S. J., Kim, M. Y., Lim, Y. L., & Kwon, S. O. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0323 · Cited by 54
Role of mesenchymal stem cells, their derived factors, and extracellular vesicles in liver failure
Wang, J., Cen, P., Chen, J., Fan, L., Li, J., Cao, H., & Li, L. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0576-4 · Cited by 50
Inagaki, Y., Higashiyama, R., & Higashi, K. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07006.x · Cited by 43
Establishment and Characterization of Immortalized Human Amniotic Epithelial Cells
Zhou, K., Koike, C., Yoshida, T., Okabe, M., Fathy, M., Kyo, S., Kiyono, T., Saito, S., & Nikaido, T. (2013) · Cellular Reprogramming · doi:10.1089/cell.2012.0021 · Cited by 39
Self-citationMetabolic Profile Changes of CCl4-Liver Fibrosis and Inhibitory Effects of Jiaqi Ganxian Granule
Wang, G., Li, Z., Li, H., Li, L., Li, J., & Yu, C. (2016) · Molecules · doi:10.3390/molecules21060698 · Cited by 24 · cited 1×
“) injection of rats twice a week with 1 mL/kg CCl4 diluted in olive oil 1:1 (v/v) for six weeks [29].”
MethodNagura, S., Otaka, S., Koike, C., Okabe, M., Yoshida, T., Fathy, M., Fukahara, K., Yoshimura, N., Misaki, T., & Nikaido, T. (2013) · Cellular Reprogramming · doi:10.1089/cell.2013.0002 · Cited by 23
Self-citationOtaka, S., Nagura, S., Koike, C., Okabe, M., Yoshida, T., Fathy, M., Yanagi, K., Misaki, T., & Nikaido, T. (2013) · Cellular Reprogramming · doi:10.1089/cell.2012.0028 · Cited by 21
Self-citationAlbright, C. D., Borgman, C., & Craciunescu, C. N. (2003) · Experimental and Molecular Pathology · doi:10.1016/s0014-4800(03)00002-9 · Cited by 19 · cited 1×
“It was reported that the inhibition of TGF-β1 suppressed the formation of 4-hydroxynonenal, which is a stable end product of lipid peroxidation and a factor of fibrotic processes, leading to mitotic activity restoration and the reduction of apoptosis in rat hepatocytes [28].”
BackgroundStemness of Human Wharton's Jelly Mesenchymal Cells Is Maintained by Floating Cultivation
Higuchi, O., Okabe, M., Yoshida, T., Fathy, M., Saito, S., Miyawaki, T., & Nikaido, T. (2012) · Cellular Reprogramming · doi:10.1089/cell.2012.0020 · Cited by 17
Self-citationDe Luna-Saldivar, M. M., Marino-Martinez, I. A., Franco-Molina, M. A., Rivera-Morales, L. G., Alarcón-Galván, G., Cordero-Pérez, P., Rojas-Martínez, A., Rodríguez-Padilla, C., & Muñoz-Espinosa, L. E. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.12.005 · Cited by 15 · cited 1×
“Furthermore, the easy arrival to subcutaneous AT, its uncomplicated isolation methods and the reproducibility to sample this tissue, make AT the most appealing source of MSCs [10].”
BackgroundEldien, H. M. S., Abdel-Aziz, H. O., Sayed, D. M., Mubarak, W., Hareedy, H. H. G., Mansor, S. G., Yoshida, T., & Fathy, M. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.08.09 · Cited by 7
Self-citationAithal, A. P., Bairy, L. K., Seetharam, R. N., & Kumar, N. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.07.04 · Cited by 5
Cited by
The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy
Li, J., Wu, Z., Zhao, L., Liu, Y., Su, Y., Gong, X., Liu, F., & Zhang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03587-y · Cited by 150
Alaaeldin, R., Abdel-Rahman, I. A. M., Hassan, H. A., Youssef, N., Allam, A. E., Abdelwahab, S. F., Zhao, Q.-L., & Fathy, M. (2021) · Molecules · doi:10.3390/molecules26247629 · Cited by 92
“Natural agents exhibited many in vitro [31,32] and in vivo [33,34] pharmacological actions in various disorders like carcinogenesis, [35] fibrosis, [36,37] angiogenesis, [38] and immunomodulation [39].”
BackgroundSelf-citationShokravi, S., Borisov, V. V., Zaman, B. A., Niazvand, F., Hazrati, R., Khah, M. M., Thangavelu, L. P., Marzban, S., Sohrabi, A. D., & Zamani, A. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02825-z · Cited by 73
“Adipose tissue Rat MSCs plus Eugenol Enhancing antifibrotic competencies of MSCs by eugenol through down-regulation of TGF-β/Smad axis [205]”
BackgroundCytokinins: Wide-Spread Signaling Hormones from Plants to Humans with High Medical Potential
Fathy, M., Eldin, S. S., Naseem, M., Dandekar, T., & Othman, E. M. (2022) · Nutrients · doi:10.3390/nu14071495 · Cited by 56
Self-citationRecent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
Metadata
- Authors
- Fathy, M., Okabe, M., Saad Eldien, H. M., & Yoshida, T.
- Affiliations
- University of Toyama (JP)
- Department of Anatomy, College of Medicine, Jouf University, Jouf 74311, Saudi Arabia
- Corresponding author
- Yoshida, Toshiko
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-01-15
- Volume
- 25
- Issue
- 2
- Pages
- 348
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7024200
- OpenAlex
- W3000324902
- Cited by
- 44
- References
- 31
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 10 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 3
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (20K12642)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- adipose-derived stem cells, eugenol, antifibrotic activity, liver fibrosis, TGF-β/Smad signaling, Smad3 phosphorylation, carbon tetrachloride-induced liver injury, combination therapy, type I collagen, alpha-smooth muscle actin, inflammatory cytokines, fibrinogen
- MeSH terms
- Animals, Anti-Infective Agents, Carbon Tetrachloride, Eugenol, Liver Cirrhosis, Male, Signal Transduction, Transforming Growth Factor beta, Rats, Sprague-Dawley, Mesenchymal Stem Cell Transplantation, Rats, Smad Proteins, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.